BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, Tassone P, Tagliaferri P. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget 2016;7:82741-56. [PMID: 27764790 DOI: 10.18632/oncotarget.12633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Qi ZY, Wang F, Yue YY, Guo XW, Guo RM, Li HL, Xu YY. CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo. J Ovarian Res 2019;12:118. [PMID: 31783885 DOI: 10.1186/s13048-019-0593-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Wang S, Zhang J, Wang T, Ren F, Liu X, Lu Y, Xu L, Zhang Y, Wang D, Xu L, Wu Y, Liu F, Li Q, Zaky MY, Liu S, Dong W, Liu F, Zou K, Zhang Y. Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer. Int J Biochem Cell Biol 2019;117:105640. [PMID: 31689531 DOI: 10.1016/j.biocel.2019.105640] [Reference Citation Analysis]
3 Zhao H, Sun Q, Li L, Zhou J, Zhang C, Hu T, Zhou X, Zhang L, Wang B, Li B, Zhu T, Li H. High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer. J Cancer 2019;10:397-407. [PMID: 30719133 DOI: 10.7150/jca.28127] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
4 Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P. The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2018;131:83-9. [DOI: 10.1016/j.critrevonc.2018.08.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
5 Zhang M, Zhang M, Wang J, Cai Q, Zhao R, Yu Y, Tai H, Zhang X, Xu C. Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy. Drug Deliv 2018;25:995-1003. [PMID: 29667478 DOI: 10.1080/10717544.2018.1461956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Crit Rev Oncol Hematol 2018;125:69-77. [PMID: 29650279 DOI: 10.1016/j.critrevonc.2018.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Xu Y, Miao C, Jin C, Qiu C, Li Y, Sun X, Gao M, Lu N, Kong B. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer. Experimental Cell Research 2018;363:160-70. [DOI: 10.1016/j.yexcr.2017.12.029] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
8 Botta C, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, Tassone P. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv 2017;1:455-66. [PMID: 29296961 DOI: 10.1182/bloodadvances.2016003905] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
9 Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Saeed-Vafa D, Cubitt C, Hakam A, Magliocco AM. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. Cancer Control 2017;24:89-95. [PMID: 28178720 DOI: 10.1177/107327481702400115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]